Significance of neurodegeneration and neuroplasticity serum biomarkers in Parkinson’s disease patients treated with subthalamic stimulation

The ability of serum biomarkers to predict the prognosis and response to deep-brain stimulation (DBS) therapy in Parkinson’s disease (PD) patients is promising. Here, we showed that NfL differed between healthy individuals and PD patients and that changes in NfL, GFAP, and BDNF occurred only transie...

Full description

Saved in:
Bibliographic Details
Published in:NPJ Parkinson's Disease 2024-10, Vol.10 (1), p.197-6, Article 197
Main Authors: Sanmartino, Florencia, Cano-Cano, Fátima, Rashid-López, Raúl, Cruz-Gómez, Álvaro Javier, Lozano-Soto, Elena, Macías-García, Paloma, Sánchez-Fernández, Francisco L., López-Sosa, Fernando, Gómez-Jaramillo, Laura, Riqué-Dormido, Jesús, Escamilla-Sevilla, Francisco, Espinosa-Rosso, Raúl, González-Rosa, Javier J.
Format: Article
Language:English
Subjects:
692/53/2422
692/617/375/346/1718
Biomarkers
Biomedical and Life Sciences
Biomedicine
Brain research
Brain-derived neurotrophic factor
Brief Communication
Electrodes
Hospitals
Medical prognosis
Neurodegeneration
Neurology
Neuroplasticity
Neurosciences
Patients
Postoperative period
Proteins
Surgery
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The ability of serum biomarkers to predict the prognosis and response to deep-brain stimulation (DBS) therapy in Parkinson’s disease (PD) patients is promising. Here, we showed that NfL differed between healthy individuals and PD patients and that changes in NfL, GFAP, and BDNF occurred only transiently after DBS surgery. Therefore, subthalamic stimulation does not promote neurodegeneration, and these biomarkers do not serve as clinical improvement endpoints in PD DBS patients.
ISSN:2373-8057
2373-8057
DOI:10.1038/s41531-024-00808-w